Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmSTU:AL21 17 Median PS Value is €0.00 as of Jul. 14, 2026. GuruFocus rates STU:AL21 with a GF Score™ of 17/100. Among 262 Healthcare Providers & Services companies, Veradigm ranks worse than 381679.01% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Veradigm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €5.352. Veradigm's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.
As of today (2026-07-14), Veradigm's share price is €3.40. Veradigm's Median PS Value is €0.00. Therefore, Veradigm's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Veradigm's Median PS Value or its related term are showing as below:
STU:AL21's Price-to-Median-PS-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.71 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Veradigm (STU:AL21) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Veradigm's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
3.40
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm Median PS Value Related Terms
Veradigm Median PS Value Historical Data
* Premium members only.
The historical data trend for Veradigm's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AL21 vs CTEV, EVH, PHR: Median PS Value Comparison
For the Health Information Services subindustry, Veradigm's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm Price-to-Median-PS-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Veradigm's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Veradigm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was €5.352.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (STU:AL21) has a Median PS Value of €0.00 as of Jul. 14, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 262 companies in the Healthcare Providers & Services industry.
Is Veradigm's Median PS Value too high?
Veradigm's current Median PS Value is €0.00. Based on the distribution chart, Veradigm ranks #999999 out of 262 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Median PS Value compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 262 companies for Median PS Value. This places Veradigm in the lower half of its industry. The industry median Median PS Value is 0.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Healthcare Providers & Services company?
The median Median PS Value among Healthcare Providers & Services companies is 0.71, based on 262 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current Median PS Value of €0.00. The current Median PS Value is €0.00. Veradigm's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Veradigm (STU:AL21), the current Median PS Value is €0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
17GF Score
Get the complete analysis for STU:AL21
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AL21 has been successfully added to your 
